Contract Services

PharmaLex joins forces with Vintura

10th December 2019

PharmaLex Group, one of the most experienced and most successful specialist providers of Development Consulting, Regulatory Affairs, Pharmacovigilance, Epidemiology & Risk Management, and Quality Management & Compliance worldwide, has entered into a joint venture with Vintura, based in Amsterdam area in the Netherlands and Munich in Germany.


Vintura is a leading strategy consultancy company specialized in life sciences and healthcare across Europe. They provide strategic and organizational design and transformation consultancy support in the pharmaceutical and medical device sector, as well as in healthcare for healthcare providers and payers.


The joint venture between PharmaLex and Vintura will provide mutual benefits for both organizations. Vintura will be able to access the vast pool of expertise offered by PharmaLex in its 31 offices in 17 countries, whilst PharmaLex will be able to build upon its already impressive service portfolio by offering clients the added value strategy and organization consulting services Vintura can provide. Both companies will continue to operate under their well-established brands.


“We are very excited to be joining forces with the PharmaLex Group”, explains Gérard Klop, Partner at Vintura. “PharmaLex has a very strong heritage in the life sciences sector and we see clear synergies between our two organizations. In addition, the international footprint of PharmaLex supports our international growth objectives”, he adds. “Vintura is an excellent partner for PharmaLex”, Dr. Thomas Dobmeyer, CEO PharmaLex, commented. “Not only do they have significant strategic experience in the life science sector, such as market access and product/portfolio strategy, they also service customers outside of our target audience, potentially allowing us to diversify our portfolio”, Thomas adds. “Being in close proximity to the European Medicines Agency is an additional advantage”. “Next to building on our mutual strengths and joint opportunities, we are also able to have more impact for our clients and society. Herewith realizing our joint ambition to create sustainable and affordable healthcare with safe and proper patient access to innovation”, both concluded.